Mucosa-Associated Lymphoid Tissue: Guardians of Immunity at Mucosal Frontiers
Main Article Content
Abstract
The mucosa-associated lymphoid tissue (MALT) stands as an intricate and versatile arm of the immune system, positioned strategically at the body's mucosal interfaces. This specialized lymphoid tissue serves as a sentinel against myriad pathogenic challenges while fostering immune tolerance to commensal microorganisms. This article explores the structural and functional attributes of MALT, delving into its critical role in immune surveillance, protection, and homeostasis within mucosal environments. We delve into the intricate interplay between MALT and its cellular constituents, focusing on the lymphocytes, follicular dendritic cells, and the diverse array of immunoglobulins. This comprehensive investigation illuminates the relevance of MALT in the context of infectious diseases, autoimmunity, and inflammation, emphasizing its potential as a therapeutic target. Additionally, we discuss the implications of MALT in the development of mucosal vaccines and the ongoing research avenues poised to unveil novel insights into this remarkable immunological asset.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. J Clin Oncol.2006;116:22-6.
II. Farinha P, Gasayne RD. Molecular pathogenesis of mucosaassociated lymphoid tissue lymphoma. J Clin Oncol. 2005;23:6370-8.
III. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96:400-19.
IV. Streubel B, Simonitsch-Klupp I, Müllauer L, Lamprecht A, Huber D, Siebert R, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leuk. 2004;18:1722-6.
V. Decaudin D, De Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006; 108:1451-60.
VI. Ferreri AJ, Penzoni M, Dognini GP, Du MQ, Doglioni C, Radford J, et al. Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. Blood. 2006;17:1721-2.
VII. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157-64.
VIII. Zucca E, Cavalli F. Are antibiotics the treatment of choice for gastric lymphoma? Curr Hematol Rep. 2004;3: 11-6.
IX. Gribben J. How I treat indolent lymphoma. Blood.2007;109:4617-26.
X. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521-38.
XI. Malfertheiner P, Megraud F, O’morain C, Bazzoli F, ElOmar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-81.
XII. Nakamura S, Yao T, Aoyagi K, Iida M, Fujishima M, Tsuneyoshi M, et al. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer. 1997;79:3-11.